Recommended

Download the very latest expert insights from environmental monitoring and microbiology professionals
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Register now for our webinar on microbial identification methods
New webinar: Process analytical technology: applications and opportunities for pharma
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
article

Formulation, Development & Delivery In-Depth Focus 2021

In this in-depth focus, experts discuss why nanoparticles are a promising alternative for delivering inflammatory bowel disease therapies and highlight the potential of antibody-drug conjugates to advance oncology treatment.

Formulation, Development & Delivery

    To read this in-depth focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Catalent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • Nanoparticles for drug delivery: next-generation biological drugs to treat inflammatory bowel diseases
      Nanoparticles offer a promising alternative to conventional drug delivery that allow for more precise targeting and controlled release. Here, Dr Fabrice Navarro discusses the benefits of these nanocarriers and their potential as a therapy for inflammatory bowel diseases (IBDs).
    • Antibody-drug conjugates: challenges, solutions and future potential
      The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.